Journal of Clinical Oncology
Articles in this Issue
Racial and insurance-based differences in nutritional anemia among hospitalized patients with head and neck cancer: A national analysis, 2016–2022.
e23200 Background: Nutritional compromise is a common and clinically important concern among patients with head and neck c...
Survival outcomes with immune checkpoint inhibitors in patients with pre-existing autoimmune disease: A global federated database analysis.
e24171 Background: Patients with pre-existing autoimmune diseases (pAI) have historically been excluded from pivotal immun...
Global trends in leukemia incidence by age, sex, and sociodemographic index: A GBD 2023 Joinpoint analysis, 2000–2023.
e18547 Background: Leukemia remains a major contributor to the global cancer burden, with incidence patterns varying by ag...
Baseline circulating tumor cells and association with early resistance in patients with metastatic breast cancer undergoing palbociclib therapy.
1111 Background: Palbociclib has significantly improved outcomes in metastatic breast cancer (MBC); however, a substantial...
From beach culture to burden: Analysis of skin cancer trends in Australasia using the GBD database (1980–2023).
e22607 Background: Australasia (Australia and New Zealand) bears a disproportionate burden of skin cancer, driven by high...
Navigated embedded supportive care via telehealth (NEST): A community-partnership model for rural oncology supportive care access.
e13534 Background: Rural Tennessee experiences disproportionately high cancer morbidity and mortality, yet utilization of...
Understanding the impact of gold and silver signals on ERAS applications: A survey of hematology/oncology fellowship program directors.
9007 Background: Since transition to virtual interviews, application and interview inflation have increased the work burde...
Phase II randomised placebo-controlled trial of melatonin for the management of sleep disturbance in women with early breast cancer on adjuvant endocrine therapy.
e12533 Background: Sleep disturbance is common among women on endocrine therapy for early breast cancer. This study invest...
Synergistic antitumor activity of GLIX1, a small molecule TET2 activator, in combination with PARP inhibition across multiple cancers.
e13129 Background: Poly(ADP-ribose) polymerase (PARP) detects single-stranded DNA breaks and marks them for repair. PARP i...
Inpatient outcomes and cost utilization by surgical approach for elective non-metastatic colon cancer resection in the United States, 2018–2023.
e23189 Background: Minimally invasive colectomy is commonly used for colon cancer resection, with increasing adoption of r...
Platinum re-challenge in platinum-resistant ovarian cancer: Real-world patterns and outcomes.
5566 Background: Platinum-resistant ovarian cancer (PROC), defined as recurrence within 6 months of completing platinum-ba...
Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor–positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
1030 Background: T-DXd improves outcomes in HR+/HER2- mBC, yet response remains heterogeneous. Treatment selection is base...
Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA).
TPS5146 Background: The androgen receptor (AR) is a key driver of prostate cancer progression. AR pathway inhibitors (ARPI...
Leveraging E7386 phase 1 trials for cardiac safety: Gaining concentration-QTc insights to inform early-stage oncology development.
e24005 Background: E7386 is a novel oral anticancer agent that inhibits the interaction between β-catenin and CREB-binding...
Brigatinib after lorlatinib and/or chemotherapy following first-line alectinib in ALK-rearranged NSCLC: Cohort B of the WJOG11919L/ABRAID study.
8606 Background: As survival improves in ALK-rearranged NSCLC, patients increasingly receive multiple lines of therapy; ho...
Immune checkpoint inhibitor therapy in patients with advanced cancer and chronic viral infections: Real-world clinical experience.
e20589 Background: Patients with chronic viral infections, including human immunodeficiency virus (HIV) and viral hepatiti...
Cellular consequences of a germline <i>SMC5</i> variant enriched in medulloblastoma.
e14112 Background: Pediatric brain tumors are the second most common pediatric malignancy and are associated with a germli...
Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome.
6570 Background: Genomic analysis is critical for accurate diagnosis and risk stratification for patients with myeloid mal...
Real-world outcomes of neoadjuvant chemo-immunotherapy in triple-negative breast cancer at a safety-net institution.
e12715 Background: The addition of immunotherapy to neoadjuvant chemotherapy for stage II-III triple negative breast cance...
Utilizing large language models for lung cancer patient education compared to publicly available information.
9019 Background: The advent of the internet, social media, and more recently of large language model (LLM) platforms has l...
Safety and efficacy of APS03118, a next-generation RET inhibitor, in patients with non-small cell lung cancer (NSCLC): Results from a phase I clinical trial.
8617 Background: Acquired resistance to first-generation selective RET inhibitors (SRIs) remains a significant clinical ch...
FAITH: Fatigue associated with immunotherapeutics—Analyzing patterns and associated factors during treatment.
e24065 Background: Fatigue is a frequent, multifactorial toxicity in patients receiving immune checkpoint inhibitors (ICIs...
Structural inequities in ovarian cancer care: A national study of hospital utilization, costs, and outcomes.
e17607 Background: Racial disparities may affect the clinical outcomes in ovarian cancer. In this study we aimed to identi...
Phase Ib evaluation of a recombinant overlapping peptide survivin immunotherapy: Safety, immunogenicity, and immune–clinical associations in advanced solid tumours.
2651 Background: Survivin (BIRC5) is a tumour-associated self-antigen broadly expressed in solid malignancies but subject...
Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.
7026 Background: Liso-cel, an autologous, CD19-directed CAR T cell product, demonstrated deep, durable responses with mana...